Parkside Financial Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $377K | Buy |
759
+24
| +3% | +$10.6K | 0.03% | 337 |
|
|
2026
Q1 | $328K | Sell |
735
-267
| -27% | -$125K | 0.03% | 332 |
|
|
2025
Q4 | $454K | Buy |
1,002
+308
| +44% | +$133K | 0.03% | 274 |
|
|
2025
Q3 | $272K | Sell |
694
-190
| -21% | -$79.4K | 0.02% | 371 |
|
|
2025
Q2 | $394K | Hold |
884
| – | – | 0.04% | 289 |
|
|
2025
Q1 | $429K | Buy |
884
+17
| +2% | +$7.92K | 0.05% | 241 |
|
|
2024
Q4 | $349K | Sell |
867
-40
| -4% | -$18.5K | 0.05% | 262 |
|
|
2024
Q3 | $422K | Buy |
907
+8
| +0.9% | +$3.84K | 0.06% | 226 |
|
|
2024
Q2 | $421K | Buy |
899
+16
| +2% | +$6.95K | 0.07% | 216 |
|
|
2024
Q1 | $369K | Buy |
883
+76
| +9% | +$32.1K | 0.06% | 239 |
|
|
2023
Q4 | $328K | Buy |
807
+162
| +25% | +$59.8K | 0.06% | 239 |
|
|
2023
Q3 | $224K | Buy |
645
+50
| +8% | +$17.5K | 0.05% | 242 |
|
|
2023
Q2 | $209K | Buy |
595
+134
| +29% | +$45.1K | 0.05% | 252 |
|
|
2023
Q1 | $145K | Buy |
461
+33
| +8% | +$9.9K | 0.04% | 296 |
|
|
2022
Q4 | $124K | Buy |
428
+13
| +3% | +$3.96K | 0.04% | 326 |
|
|
2022
Q3 | $120K | Buy |
415
+7
| +2% | +$2.01K | 0.04% | 298 |
|
|
2022
Q2 | $115K | Buy |
408
+26
| +7% | +$6.96K | 0.04% | 304 |
|
|
2022
Q1 | $99K | Buy |
382
+30
| +9% | +$7.12K | 0.03% | 365 |
|
|
2021
Q4 | $77K | Buy |
352
+28
| +9% | +$5.45K | 0.02% | 418 |
|
|
2021
Q3 | $58K | Buy |
324
+7
| +2% | +$1.37K | 0.02% | 466 |
|
|
2021
Q2 | $64K | Buy |
317
+21
| +7% | +$4.39K | 0.02% | 442 |
|
|
2021
Q1 | $63K | Sell |
296
-9
| -3% | -$1.98K | 0.02% | 420 |
|
|
2020
Q4 | $72K | Sell |
305
-19
| -6% | -$4.36K | 0.02% | 370 |
|
|
2020
Q3 | $88K | Sell |
324
-3
| -0.9% | -$828 | 0.03% | 317 |
|
|
2020
Q2 | $95K | Sell |
327
-50
| -13% | -$13.6K | 0.03% | 315 |
|
|
2020
Q1 | $90K | Buy |
377
+26
| +7% | +$5.96K | 0.03% | 275 |
|
|
2019
Q4 | $77K | Buy |
351
+33
| +10% | +$6.68K | 0.02% | 343 |
|
|
2019
Q3 | $54K | Buy |
318
+9
| +3% | +$1.59K | 0.02% | 397 |
|
|
2019
Q2 | $57K | Buy |
309
+11
| +4% | +$1.92K | 0.02% | 375 |
|
|
2019
Q1 | $55K | Sell |
298
-25
| -8% | -$4.62K | 0.02% | 365 |
|
|
2018
Q4 | $54K | Buy |
323
+48
| +17% | +$8.32K | 0.02% | 341 |
|
|
2018
Q3 | $53K | Hold |
275
| – | – | 0.02% | 357 |
|
|
2018
Q2 | $47K | Sell |
275
-81
| -23% | -$12.6K | 0.02% | 371 |
|
|
2018
Q1 | $58K | Buy |
356
+7
| +2% | +$1.14K | 0.02% | 318 |
|
|
2017
Q4 | $52K | Sell |
349
-11
| -3% | -$1.63K | 0.02% | 353 |
|
|
2017
Q3 | $55K | Buy |
360
+34
| +10% | +$5.12K | 0.02% | 327 |
|
|
2017
Q2 | $42K | Buy |
326
+126
| +63% | +$15.2K | 0.02% | 372 |
|
|
2017
Q1 | $22K | Buy |
200
+10
| +5% | +$880 | 0.01% | 511 |
|
|
2016
Q4 | $14K | Sell |
190
-14
| -7% | -$1.14K | 0.01% | 619 |
|
|
2016
Q3 | $18K | Buy |
204
+8
| +4% | +$756 | 0.01% | 593 |
|
|
2016
Q2 | $17K | Sell |
196
-60
| -23% | -$5.18K | 0.01% | 580 |
|
|
2016
Q1 | $20K | Buy |
256
+19
| +8% | +$1.72K | 0.01% | 523 |
|
|
2015
Q4 | $30K | Sell |
237
-63
| -21% | -$7.61K | 0.01% | 428 |
|
|
2015
Q3 | $31K | Buy |
+300
| New | +$38.5K | 0.02% | 392 |
|
Other funds holding VRTX
Parkside Financial Bank & Trust's VRTX Position: Q2 2026 in Review
Parkside Financial Bank & Trust increased its Vertex Pharmaceuticals (VRTX) stake by 3.3% in Q2 2026, buying an estimated $10.6K and bringing the position to 759 shares worth $377K. The position accounts for 0.03% of the portfolio, ranked #337.
Parkside Financial Bank & Trust first reported a position in VRTX in Q3 2015 and has held it in 44 quarters since. The position peaked at $454K in Q4 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Parkside Financial Bank & Trust held 759 shares of Vertex Pharmaceuticals worth $377K as of Q2 2026.
- Parkside Financial Bank & Trust bought 24 Vertex Pharmaceuticals shares in Q2 2026, an estimated $10.6K.
- Vertex Pharmaceuticals made up 0.03% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #337 holding.
- Parkside Financial Bank & Trust first reported a position in Vertex Pharmaceuticals in Q3 2015 and has held it in 44 quarters since.
- Parkside Financial Bank & Trust's Vertex Pharmaceuticals position peaked at $454K in Q4 2025.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.